BPMC240920C85000
- 3.52
- 0.000.00%
Blueprint Medicines Newsroom
Blueprint Announces the Hiring of Industry Veteran John Smelter to Medical Outpatient Team
Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines Corporation's (NASDAQ:BPMC) Business Is Yet to Catch Up With Its Share Price
Blueprint Prep's Annual $20,000 Medical School Scholarship Now Open for Submissions
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)
Blueprint Medicines (NASDAQ:BPMC) Has Debt But No Earnings; Should You Worry?
9 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing
Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 4.32 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 5, $Blueprint Medicines(BPMC.US)$ Officer Lee Philina intends to sell 46,436 shares of its common stock on Aug 5, with a total market value of approximately $4.32 million.
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Blueprint Medicines(BPMC.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 17.7% over
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Raises Target Price to $105
Barclays analyst Peter Lawson maintains $Blueprint Medicines(BPMC.US)$ with a hold rating, and adjusts the target price from $70 to $105.According to TipRanks data, the analyst has a success rate of 4
Blueprint Medicines (BPMC) Receives a Hold From Barclays
Blueprint Medicines Second Quarter 2024 Earnings: Beats Expectations
Blueprint Medicines Price Target Raised to $138.00/Share From $130.00 by Guggenheim